Opthea Ltd to Host Investor Days in NY and Australia
Ticker: OPTEY · Form: 6-K · Filed: Jan 8, 2025 · CIK: 1815620
Sentiment: neutral
Topics: investor-relations, biotech, announcement
TL;DR
Opthea holding investor days in NY/Aus Jan 2025 - expect updates on their eye drug pipeline.
AI Summary
Opthea Limited announced on January 8, 2025, that it will host investor days in New York and Australia. These events will provide updates on the company's development programs and strategic priorities. The company is focused on its novel biologic therapies for serious eye conditions.
Why It Matters
These investor days offer a platform for Opthea to communicate its progress and future plans directly to investors, potentially influencing market perception and investment decisions.
Risk Assessment
Risk Level: medium — The company is in the biotechnology sector, which inherently carries high development and regulatory risks, though this filing itself is a routine announcement.
Key Players & Entities
- Opthea Limited (company) — Registrant
- January, 2025 (date) — Reporting period for the 6-K
- New York (location) — Location for investor day
- Australia (location) — Location for investor day
FAQ
What is the purpose of the investor days announced by Opthea Limited?
The investor days are intended to provide updates on Opthea's development programs and strategic priorities.
When was this Form 6-K filed?
This Form 6-K was filed on January 8, 2025.
Where will the investor days be held?
The investor days will be held in New York and Australia.
What type of company is Opthea Limited?
Opthea Limited is a company in the Biological Products sector, specifically focusing on therapies for serious eye conditions.
What exhibit is included with this filing?
Exhibit 99.1 is included, which is a Press Release announcing Opthea's investor days.
Filing Stats: 152 words · 1 min read · ~1 pages · Grade level 13.1 · Accepted 2025-01-08 06:02:54
Filing Documents
- opt_-_opthea_investor_da.htm (6-K) — 24KB
- opt-ex99_1.htm (EX-99.1) — 29KB
- img260626642_0.jpg (GRAPHIC) — 61KB
- img260626642_1.jpg (GRAPHIC) — 61KB
- 0000950170-25-003203.txt ( ) — 222KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereto duly authorized. OPTHEA LIMITED (Registrant) By: /s/ Frederic Guerard Name: Frederic Guerard Title: Chief Executive Officer Date: 01/08/2025